There are currently 552 clinical trials in Charlotte, North Carolina looking for participants to engage in research studies. Trials are conducted at various facilities, including Carolinas Medical Center, Carolinas Medical Center/Levine Cancer Institute, Novant Health Presbyterain Medical Center and Levine Cancer Institute. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
International Spontaneous Coronary Artery Dissection (SCAD) "iSCAD" Registry
NCT04496687
Recruiting
The aim of "iSCAD," the International Spontaneous Coronary Artery Dissection (SCAD) Registry, is to serve as an internationally collaborative, multicenter registry coordinated by an experienced and centralized coordinating center in an effort to increase the pace of participant recruitment, and thereby increase statistical power of studies related to SCAD. The ultimate goal of iSCAD Registry is to facilitate the development of best practices and clinical guidelines for preventing SCAD or its re... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
08/16/2023
Locations: Atrium Health Sanger Heart and Vascular Institute, Charlotte, North Carolina
Conditions: Spontaneous Coronary Artery Dissection
Register for Updates
Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma
NCT05079282
Recruiting
This study will investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ONO-4685 in patients with relapsed or refractory T cell Lymphoma
Gender:
All
Ages:
18 years and above
Trial Updated:
08/16/2023
Locations: Novant Health Presbyterian Medical Center, Charlotte, North Carolina
Conditions: Relapsed or Refractory T Cell Lymphoma
Register for Updates
Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia
NCT03121586
Recruiting
To evaluate the long-term safety and tolerability of pimavanserin after 52 weeks of adjunctive treatment in subjects with schizophrenia
Gender:
All
Ages:
18 years and above
Trial Updated:
08/15/2023
Locations: 106-New Hope Clinical Research, Charlotte, North Carolina
Conditions: Schizophrenia
Register for Updates
TENS and Perioperative Fracture Patients
NCT04209673
Recruiting
This is a pilot study designed to evaluate the effectiveness of TENS as part of post-operative pain management. Subjects receiving a TENS unit as part of clinical practice will be approached for consent and followed for 12 months.
Gender:
All
Ages:
18 years and above
Trial Updated:
08/14/2023
Locations: Carolinas Medical Center, Department of Orthopaedic Surgery, Charlotte, North Carolina
Conditions: Musculoskeletal Pain
Register for Updates
S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration
NCT04071457
Recruiting
Patients are enrolled to screening (Reg Step 1) prior to or after ASCT but prior to Reg Step 2. Patients are followed until they will begin Maintenance and then registered to Reg Step 2 (first randomization). Patients are randomized between Lenalidomide for 2 years and Lenalidomide + Daratumumab/rHuPH20. After 2 years of Maintenance, MRD is assessed to guide further therapy. MRD-positive patients will continue with the assigned treatment. MRD-negative patients will be further randomized (Reg Ste... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
08/11/2023
Locations: Carolinas Medical Center/Levine Cancer Institute, Charlotte, North Carolina
Conditions: Multiple Myeloma
Register for Updates
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
NCT04205968
Recruiting
This phase II trial studies how well ramucirumab and paclitaxel or the FOLFIRI regimen (leucovorin calcium, fluorouracil, and irinotecan hydrochloride) work in treating patients with small bowel cancers that have spread extensively to other anatomic sites (advanced) or are no longer responding to treatment (refractory). Ramucirumab is a monoclonal antibody that attaches to and inhibits a molecule called VEGFR-2. This may restrain new blood vessel formation therefore reducing nutrient supply to t... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
08/11/2023
Locations: Carolinas Medical Center/Levine Cancer Institute, Charlotte, North Carolina +3 locations
Conditions: Metastatic Small Intestinal Adenocarcinoma, Stage III Small Intestinal Adenocarcinoma AJCC v8, Stage IIIA Small Intestinal Adenocarcinoma AJCC v8, Stage IIIB Small Intestinal Adenocarcinoma AJCC v8, Stage IV Small Intestinal Adenocarcinoma AJCC v8
Register for Updates
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
NCT03678025
Recruiting
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.
Gender:
Male
Ages:
18 years and above
Trial Updated:
08/11/2023
Locations: Carolinas Medical Center/Levine Cancer Institute, Charlotte, North Carolina +3 locations
Conditions: Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Register for Updates
Evaluating the Safety and Efficacy of Polyethylene Glycol (PEG) Mediated Fusion (PEG Fusion)
NCT04789044
Recruiting
The overall objective of this study is to determine the safety of PEG fusion when used with primary repair or reconstruction in patients with an acute upper extremity peripheral nerve injury. PEG is safe and effective for extending the half-life of circulating pharmaceutical products, when used in conjunction with a topical hemostatic agent in surgical wounds, and when used as a colon cleanser for endoscopic surgical procedures. However, PEG fusion has not been rigorously tested as a safe reagen... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
08/10/2023
Locations: OrthoCarolina, Charlotte, North Carolina
Conditions: Peripheral Nerve Injuries
Register for Updates
Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors
NCT04337177
Recruiting
A pilot pharmacokinetic trial to determine the safety and efficacy of a flavored, orally administered irinotecan VAL-413 (Orotecan®) given with temozolomide for treatment of recurrent pediatric solid tumors including but not limited to neuroblastoma, rhabdomyosarcoma, Ewing sarcoma, hepatoblastoma and medulloblastoma
Gender:
All
Ages:
Between 1 year and 30 years
Trial Updated:
08/10/2023
Locations: Atrium Health Levine Children's Hospital - Carolinas Medical Center, Charlotte, North Carolina
Conditions: Solid Tumors, Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma, Hepatoblastoma, Medulloblastoma
Register for Updates
Study Comparing Investigational Drug HBI-8000 Combined With Nivolumab vs. Nivolumab in Patients With Advanced Melanoma
NCT04674683
Recruiting
This is a phase 3 study to compare the efficacy and safety of HBI-8000 or Placebo combined with nivolumab on patients with unresectable or metastatic melanoma and eligible patients who are not adolescents or patients with new, progressive brain metastasis will be stratified by PD-L1 expression and LDH level.
Gender:
All
Ages:
12 years and above
Trial Updated:
07/25/2023
Locations: Levine Cancer Institute, Charlotte, North Carolina
Conditions: Unresectable or Metastatic Melanoma, Progressive Brain Metastasis
Register for Updates
Registry of Avance® Nerve Graft's Utilization and Recovery Outcomes Post Peripheral Nerve Reconstruction
NCT01526681
Recruiting
This study is a registry of general use of Avance Nerve Graft and is intended to evaluate the uses, response rates, and safety of Avance Nerve Graft in the real-life clinical setting. Optional addendums 1 and 2 included in the protocol are intended to establish comparative groups and focused subgroups within the registry.
Gender:
All
Ages:
All
Trial Updated:
07/17/2023
Locations: RANGER & MATCH: OrthoCarolina Research Institute, Inc., Charlotte, North Carolina
Conditions: Peripheral Nerve Injuries
Register for Updates
Addressing Barriers to Achieving Cardiometabolic Disorders Prevention and Treatment Goals for PLWH in the SE US
NCT05129345
Recruiting
This study has 3 aims. Aim 1: Identify social determinants of cardiometabolic health and determine facilitators and modifiable barriers in achieving treatment goals. Aim 2: Assess PLWH knowledge, skills, and confidence for self-management of cardiometabolic disorders. Aim 3: Tailor a self-management support and education intervention with stakeholder input to address barriers to achieving treatment goals for cardiometabolic disorders in PLWH at the study sites.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/11/2023
Locations: Duke University - Charlotte Study Sites, Charlotte, North Carolina
Conditions: Hypertension, Dyslipidemias, Type 2 Diabetes, HIV-1-infection
Register for Updates